Hypertension
Conference Coverage
Black HFrEF patients get more empagliflozin benefit in EMPEROR analyses
Empagliflozin trial data in patients with heart failure with reduced ejection fraction signal more benefit in Black, compared with White patients...
From the Journals
High lipoprotein(a) levels plus hypertension add to CVD risk
A new analysis illustrates, for the first time, a significant interaction between Lp(a) and hypertension in the primary prevention of...
From the Journals
Chlorthalidone, HCTZ equally effective in hypertension: DCP published
The Diuretic Comparison Project trial, showing no difference in clinical events between diuretics chlorthalidone and hydrochlorothiazide for...
Guidelines
ADA issues 2023 ‘Standards of Care’ for diabetes: Focus on tight BP, lipids
The new 2023 American Diabetes Association Standards of Care address management of diabetes and its complications, as well as social determinants...
Feature
How your voice could reveal hidden disease
For some of us, when a disease begins or when our mental health declines, our voice changes.
From the Journals
Gestational hypertension-diabetes combo signals CVD risk
Having both hypertensive disorders and diabetes while pregnant ups later cardiovascular risk, suggesting greater care is needed when these...
Commentary
New studies change beliefs about cardiovascular disease
Why it doesn't matter if you take your antihypertensive agent in the morning or the evening explained.
Conference Coverage
Be aware, mindfulness training can lower systolic BP: MB-BP
“This is exactly what we need: a well-done trial with a control group to show that it actually works,” said one expert, cautioning that it...
From the Journals
Hypertension linked to risk of severe COVID
A new study out of the United Kingdom identifies at what level high blood pressure can help predict a life-threatening case of the virus.
Conference Coverage
Baxdrostat slashes BP in resistant hypertension: BrigHTN
The novel agent lowers aldosterone activity without the off-target inhibition of cortisol synthesis that has thwarted previous drug candidates,...
Conference Coverage
Sham-controlled renal denervation trial for hypertension is a near miss
The SPYRAL HTN–ON MED trial missed its primary endpoint, likely caused in part by imbalances in medication use.